Objective To review clinical validation or implementation studies of maternal blood cell‐free
(cf) DNA analysis and define the performance of screening for fetal trisomies 21, 18 and 13 …

Background Cell‐free fetal DNA (cff DNA) non‐invasive prenatal testing (NIPT) is rapidly
expanding, and is being introduced at varying rates depending on country and condition …

Disclaimer: This statement is designed primarily as an educational resource for clinicians to
help them provide quality medical services. Adherence to this statement is completely …

Background: In pregnant women at risk of autosomal recessive (AR) disorders, prenatal
diagnosis of AR disorders primarily involves invasive procedures, such as chorionic villus …

Background Common fetal aneuploidies include Down syndrome (trisomy 21 or T21),
Edward syndrome (trisomy 18 or T18), Patau syndrome (trisomy 13 or T13), Turner …

Background Noninvasive prenatal testing (NIPT) for fetal aneuploidies by scanning cell-free
fetal DNA in maternal plasma is rapidly becoming a first-tier aneuploidy screening test in …

Objective Recent non-invasive prenatal testing (NIPT) technologies are based on next-
generation sequencing (NGS). NGS allows rapid and effective clinical diagnoses to be …

Noninvasive prenatal testing (NIPT) using sequencing of fetal cell-free DNA from maternal
plasma has enabled accurate prenatal diagnosis of aneuploidy and become increasingly …

Objectives Embryonic numerical and structural chromosomal abnormalities are the most
common cause of early pregnancy loss. However, the role of submicroscopic copy‐number …

Background: Non-invasive prenatal testing (NIPT) for aneuploidy in pregnant women
screening has been recently established in Saudi Arabia. We aim from this study to report …